Lumena Pharmaceuticals is focused on advancing treatments in metabolic diseases that have high unmet clinical needs by expanding the role of bile acids.

• Primary contact for management of partnership relationships including resource allocation decisions and issue resolution.• Initiated implementation of program and alliance management practices across clinical pipeline following the in-licensing of three clinical stage assets over a three month period, including oversight of the development of FDA worthy quality system to support clinical pipeline.• Built complex financial models to drive decision making for product/company acquisitions, business divestiture and corporate strategic process.• Assumed responsibility for Rheumatology diagnostic business unit in Sept 2009, reduced operating budget by 40%, streamlined staffing model, increased net revenues by 50% and improved operational processes. • Established corporate partnership programs with large pharma and national pharmacy benefit management companies to increase testing volume and leverage marketing programs at little or no cost to Cypress. • Conducted comprehensive process to identify potential acquirers for diagnostic business unit from preliminary contact to final negotiation of terms and purchase contracts. • Responsible for wind-down of commercial organization following decision to divest sales force.

• Responsible for management of partnership with Forest Labs on company’s lead program, Savella® for Fibromyalgia. Including management of clinical development program strategy, budgets and timelines. Resulting in the Dec 2007 NDA filing and Jan 2009 product approval.• Provided oversight and direction for pipeline program teams, ensuring adherence to approved program plans, budgets and timelines. • Primary contact for management of partnership relationships including resource allocation decisions and issue resolution.• Led exhaustive business development effort to identify products in the Rheumatology and Pain space to complement Cypress’s strategic vision.

Develop and execute strategic development plans to maximize asset value, streamline clinical development and manage risk. Manage and facilitate the progression of products through research and development. Manage alliance relationships with national and international partners. Facilitate information flow from program teams to the executive team. Proactively identify potential roadblocks and risks and determine appropriate contingency strategies.• Actively managed alliance programs with partners including Genentech and PDL Biopharma, promoting information sharing practices and timely decision making. • Succeeded in transitioning two programs from research to development (initiation of IND-enabling studies) in parallel, on or ahead of time while satisfying predetermined criteria for efficacy, toxicity and CMC readiness. • Contributed to drug development team management across the value chain, including preparation of regulatory submissions, protocol review, market analysis, financial projections, supply chain management and experimental design. Developed detailed financial/market models to enable life cycle management decision-making. • Expertise in leading geographically dispersed and culturally diverse teams.• Internal consultant for Biogen Idec New Ventures Group diligence efforts.• Managed a portfolio of 6 programs across indications (oncology and immunology), sites and collaborations. • Initiated and managed vendor contracts/relationships ensuring timely delivery of services or product.• Led the integration of IDEC research projects into post-merger Biogen Idec research portfolio. Initiated restructuring of large (~60 person) research team tasked with parallel evaluation of candidate oncology targets, developed new communication tools and increased team member accountability.